## Philip E Empey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1184551/publications.pdf

Version: 2024-02-01

136740 149479 3,721 96 32 56 citations h-index g-index papers 99 99 99 4436 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	<scp>PharmVar GeneFocus</scp> : <scp><i>SLCO1B1</i></scp> . Clinical Pharmacology and Therapeutics, 2023, 113, 782-793.	2.3	18
2	Pharmacists Leading the Way to Precision Medicine: Updates to the Core Pharmacist Competencies in Genomics. American Journal of Pharmaceutical Education, 2022, 86, 8634.	0.7	21
3	Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. Clinical and Translational Science, 2022, 15, 371-383.	1.5	13
4	A Multidisciplinary Precision Medicine Service in Primary Care. Annals of Family Medicine, 2022, 20, 88-88.	0.9	6
5	<i>CYP2C19</i> Genotypeâ€Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. Journal of the American Heart Association, 2022, 11, e024159.	1.6	24
6	Bestâ€"worst scaling methodology to evaluate constructs of the Consolidated Framework for Implementation Research: application to the implementation of pharmacogenetic testing for antidepressant therapy. Implementation Science Communications, 2022, 3, 52.	0.8	4
7	Glibenclamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2021, 38, 628-645.	1.7	20
8	Impact of the <i>CYP2C19*17</i> Allele on Outcomes in Patients Receiving Genotypeâ€Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. Clinical Pharmacology and Therapeutics, 2021, 109, 705-715.	2.3	25
9	A pilot study of oral treprostinil pharmacogenomics and treatment persistence in patients with pulmonary arterial hypertension. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110136.	1.0	4
10	Expanding evidence leads to new pharmacogenomics payer coverage. Genetics in Medicine, 2021, 23, 830-832.	1.1	49
11	Opportunity for Genotypeâ€Guided Prescribing Among Adult Patients in 11 US Health Systems. Clinical Pharmacology and Therapeutics, 2021, 110, 179-188.	2.3	35
12	Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genetics in Medicine, 2021, 23, 2335-2341.	1.1	32
13	Kollidon VA64 Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2021, 38, 2454-2472.	1.7	5
14	Documenting Pharmacogenomic Test Results in Electronic Health Records: Practical Considerations for Primary Care Teams. Journal of Personalized Medicine, 2021, 11, 1296.	1.1	9
15	Paths to Successful Translation of New Therapies for Severe Traumatic Brain Injury in the Golden Age of Traumatic Brain Injury Research: A Pittsburgh Vision. Journal of Neurotrauma, 2020, 37, 2353-2371.	1.7	31
16	Translational Informatics Connects Realâ€World Information to Knowledge in an Increasingly Dataâ€Driven World. Clinical Pharmacology and Therapeutics, 2020, 107, 738-741.	2.3	2
17	Evaluating the extent of reusability of CYP2C19 genotype data among patients genotyped for antiplatelet therapy selection. Genetics in Medicine, 2020, 22, 1898-1902.	1.1	9
18	Variant Interpretation in Current Pharmacogenetic Testing. Journal of Personalized Medicine, 2020, 10, 204.	1.1	5

#	Article	IF	Citations
19	Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data. Pharmacogenomics Journal, 2020, 20, 724-735.	0.9	25
20	Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Network Open, 2020, 3, e2029411.	2.8	34
21	Advanced Pharmacy Practice Experiences in Pharmacogenomics Offered by US Pharmacy Programs. American Journal of Pharmaceutical Education, 2020, 84, ajpe8031.	0.7	8
22	Participatory Genomic Testing Can Effectively Disseminate Cardiovascular Pharmacogenomics Concepts within Federally Qualified Health Centers: A Feasibility Study. Ethnicity and Disease, 2020, 30, 167-176.	1.0	1
23	The "All of Us―Research Program. New England Journal of Medicine, 2019, 381, 668-676.	13.9	955
24	Community pharmacists' educational needs for implementing clinical pharmacogenomic services. Journal of the American Pharmacists Association: JAPhA, 2019, 59, 539-544.	0.7	17
25	Affiliate network members as force amplifiers of genomic medicine research. Personalized Medicine, 2019, 16, 431-433.	0.8	0
26	Nitrite pharmacokinetics, safety and efficacy after experimental ventricular fibrillation cardiac arrest. Nitric Oxide - Biology and Chemistry, 2019, 93, 71-77.	1.2	6
27	Multi-Focal Neuronal Ultrastructural Abnormalities and Synaptic Alterations in Mice after Low-Intensity Blast Exposure. Journal of Neurotrauma, 2019, 36, 2117-2128.	1.7	16
28	Engaging and Empowering Stakeholders to Advance Pharmacogenomics. Clinical Pharmacology and Therapeutics, 2019, 106, 305-308.	2.3	5
29	Factors Contributing to Fentanyl Pharmacokinetic Variability Among Diagnostically Diverse Critically Ill Children. Clinical Pharmacokinetics, 2019, 58, 1567-1576.	1.6	5
30	Confirmation of Selected Synergistic Cancer Drug Combinations Identified in an HTS Campaign and Exploration of Drug Efflux Transporter Contributions to the Mode of Synergy. SLAS Discovery, 2019, 24, 653-668.	1.4	7
31	Design and testing of Medivate, a mobile app to achieve medication list portability via Fast Healthcare InteroperabilityÂResources. Journal of the American Pharmacists Association: JAPhA, 2019, 59, S78-S85.e2.	0.7	10
32	Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genetics in Medicine, 2019, 21, 2255-2263.	1.1	53
33	Membrane transporters in traumatic brain injury: Pathological, pharmacotherapeutic, and developmental implications. Experimental Neurology, 2019, 317, 10-21.	2.0	5
34	Opioid e-prescribing trends at discharge in a large pediatric health system. Journal of Opioid Management, 2019, 15, 119-127.	0.2	4
35	Regionally clustered <i>ABCC8</i> polymorphisms in a prospective cohort predict cerebral oedema and outcome in severe traumatic brain injury. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1152-1162.	0.9	36
36	Operation Brain Trauma Therapy: 2016 Update. Military Medicine, 2018, 183, 303-312.	0.4	41

#	Article	IF	Citations
37	Multisite Investigation of Strategies for the Implementation of ⟨i⟩CYP2C19⟨/i⟩ Genotypeâ€Guided Antiplatelet Therapy. Clinical Pharmacology and Therapeutics, 2018, 104, 664-674.	2.3	94
38	<i>ABCG2</i> c.421C> A Is Associated with Outcomes after Severe Traumatic Brain Injury. Journal of Neurotrauma, 2018, 35, 48-53.	1.7	13
39	Multisite Investigation of Outcomes WithÂlmplementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 181-191.	1.1	213
40	880: ARDA2A AND CYP3A5 GENOTYPES ARE ASSOCIATED WITH FENTANYL REQUIREMENTS IN CRITICALLY ILL CHILDREN. Critical Care Medicine, 2018, 46, 424-424.	0.4	2
41	Therapeutic Hypothermia in Cardiac Arrest. Therapeutic Hypothermia and Temperature Management, 2018, 8, 195-198.	0.3	0
42	Clinical Pharmacogenomics. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1561-1571.	2.2	18
43	Usefulness of Intravenous Sodium Nitrite During Resuscitation for the Treatment of Out-of-Hospital Cardiac Arrest. American Journal of Cardiology, 2018, 122, 554-559.	0.7	11
44	Exploratory Application of Neuropharmacometabolomics in Severe Childhood Traumatic Brain Injury*. Critical Care Medicine, 2018, 46, 1471-1479.	0.4	14
45	Multi-Center Pre-clinical Consortia to Enhance Translation of Therapies and Biomarkers for Traumatic Brain Injury: Operation Brain Trauma Therapy and Beyond. Frontiers in Neurology, 2018, 9, 640.	1.1	42
46	Delivering on the value proposition of precision medicine: the view from healthcare payers. American Journal of Managed Care, 2018, 24, 177-179.	0.8	6
47	Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of <i>N</i> -acetylcysteine. Xenobiotica, 2017, 47, 346-353.	0.5	39
48	Information needs for making clinical recommendations about potential drug-drug interactions: a synthesis of literature review and interviews. BMC Medical Informatics and Decision Making, 2017, 17, 21.	1.5	25
49	Design and evaluation of a pharmacogenomics information resource for pharmacists. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 822-831.	2.2	5
50	ABCB1 genotype is associated with fentanyl requirements in critically ill children. Pediatric Research, 2017, 82, 29-35.	1.1	19
51	The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Realâ€World Setting. Clinical and Translational Science, 2017, 10, 143-146.	1.5	82
52	The pharmacogenomics of severe traumatic brain injury. Pharmacogenomics, 2017, 18, 1413-1425.	0.6	15
53	Precision Medicine in Critical Care Requires an Understanding of Pharmacokinetic Variability*. Pediatric Critical Care Medicine, 2017, 18, 728-729.	0.2	0
54	ABCC8 Single Nucleotide Polymorphisms are Associated with Cerebral Edema in Severe TBI. Neurocritical Care, 2017, 26, 213-224.	1.2	40

#	Article	IF	Citations
55	Drug Metabolism in Cardiovascular Disease. , 2017, , 139-156.		O
56	Blended Simulation Progress Testing for Assessment of Practice Readiness. American Journal of Pharmaceutical Education, 2017, 81, 14.	0.7	19
57	Phase I randomized clinical trial of N-acetylcysteine in combination with an adjuvant probenecid for treatment of severe traumatic brain injury in children. PLoS ONE, 2017, 12, e0180280.	1.1	39
58	Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available. PLoS ONE, 2016, 11, e0164972.	1.1	68
59	Cyclosporine Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 553-566.	1.7	44
60	Educational strategies to enable expansion of pharmacogenomics-based care. American Journal of Health-System Pharmacy, 2016, 73, 1986-1998.	0.5	79
61	Pharmacogenomics to achieve precision medicine. American Journal of Health-System Pharmacy, 2016, 73, 1906-1907.	0.5	7
62	Effect of Hypothermia and Targeted Temperature Management on Drug Disposition and Response Following Cardiac Arrest: A Comprehensive Review of Preclinical and Clinical Investigations. Therapeutic Hypothermia and Temperature Management, 2016, 6, 169-179.	0.3	46
63	Bringing clinical pharmacogenomics information to pharmacists: A qualitative study of information needs and resource requirements. International Journal of Medical Informatics, 2016, 86, 54-61.	1.6	27
64	Probenecid and $\langle i \rangle N \langle i \rangle$ -Acetylcysteine Prevent Loss of Intracellular Glutathione and Inhibit Neuronal Death after Mechanical Stretch Injury $\langle i \rangle$ In Vitro $\langle i \rangle$ . Journal of Neurotrauma, 2016, 33, 1913-1917.	1.7	19
65	Advancing Pharmacogenomics Education in the Core PharmD Curriculum through Student Personal Genomic Testing. American Journal of Pharmaceutical Education, 2016, 80, 3.	0.7	73
66	Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 567-580.	1.7	40
67	Synthesis of Findings, Current Investigations, and Future Directions: Operation Brain Trauma Therapy. Journal of Neurotrauma, 2016, 33, 606-614.	1.7	61
68	Expression of ATP-Binding Cassette Transporters B1 and C1 after Severe Traumatic Brain Injury in Humans. Journal of Neurotrauma, 2016, 33, 226-231.	1.7	18
69	Combination Therapies for Traumatic Brain Injury: Retrospective Considerations. Journal of Neurotrauma, 2016, 33, 101-112.	1.7	56
70	Adding evidence type representation to DIDEO. CEUR Workshop Proceedings, 2016, 1747, .	2.3	0
71	Dexmedetomidine Reduces Shivering during Mild Hypothermia in Waking Subjects. PLoS ONE, 2015, 10, e0129709.	1.1	35
72	Emerging Therapies in Traumatic Brain Injury. Seminars in Neurology, 2015, 35, 083-100.	0.5	100

#	Article	IF	CITATIONS
73	Interpatient Variability in Dexmedetomidine Response: A Survey of the Literature. Scientific World Journal, The, 2014, 2014, 1-12.	0.8	38
74	Barriers to Drug Delivery for Brain Trauma. , 2014, , 125-140.		1
75	Patient Predictors of Dexmedetomidine Effectiveness for Sedation in Intensive Care Units. American Journal of Critical Care, 2014, 23, 160-165.	0.8	20
76	In vitro transport characteristics of EFdA, a novel nucleoside reverse transcriptase inhibitor using Caco-2 and MDCKII cell monolayers. European Journal of Pharmacology, 2014, 732, 86-95.	1.7	15
77	Towards a foundational representation of potential drug-drug interaction knowledge. CEUR Workshop Proceedings, 2014, 1309, 16-31.	2.3	3
78	Influence of ATP-Binding Cassette Polymorphisms on Neurological Outcome After Traumatic Brain Injury. Neurocritical Care, 2013, 19, 192-198.	1.2	27
79	Therapeutic Hypothermia Decreases Phenytoin Elimination in Children with Traumatic Brain Injury*. Critical Care Medicine, 2013, 41, 2379-2387.	0.4	50
80	Drug Dosing During Hypothermia. Pediatric Critical Care Medicine, 2013, 14, 228-229.	0.2	5
81	Toward semantic modeling of pharmacogenomic knowledge for clinical and translational decision support. AMIA Summits on Translational Science Proceedings, 2013, 2013, 28-32.	0.4	3
82	Stereoselective Interaction of Pantoprazole with ABCG2. II. In Vitro Flux Analysis. Drug Metabolism and Disposition, 2012, 40, 1024-1031.	1.7	7
83	Mild hypothermia decreases fentanyl and midazolam steady-state clearance in a rat model of cardiac arrest. Critical Care Medicine, 2012, 40, 1221-1228.	0.4	51
84	Core Competencies for Research Training in the Clinical Pharmaceutical Sciences. American Journal of Pharmaceutical Education, 2011, 75, 27.	0.7	27
85	Cardiac Arrest and Therapeutic Hypothermia Decrease Isoform-Specific Cytochrome P450 Drug Metabolism. Drug Metabolism and Disposition, 2011, 39, 2209-2218.	1.7	31
86	Genetic predisposition to adverse drug reactions in the intensive care unit. Critical Care Medicine, 2010, 38, S106-S116.	0.4	52
87	Endothelin-1 Is Increased in Cerebrospinal Fluid and Associated with Unfavorable Outcomes in Children after Severe Traumatic Brain Injury. Journal of Neurotrauma, 2010, 27, 1819-1825.	1.7	61
88	Mild Hypothermia Alters Midazolam Pharmacokinetics in Normal Healthy Volunteers. Drug Metabolism and Disposition, 2010, 38, 781-788.	1.7	73
89	Lipid Emulsion Combined with Epinephrine and Vasopressin Does Not Improve Survival in a Swine Model of Bupivacaine-induced Cardiac Arrest. Anesthesiology, 2009, 111, 138-146.	1.3	85
90	N-(4-[2-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine Carboxamide (GF120918) As a Chemical ATP-Binding Cassette Transporter Family G Member 2 (Abcg2) Knockout Model to Study Nitrofurantoin Transfer into Milk. Drug Metabolism and Disposition, 2008, 36, 2591-2596.	1.7	13

## PHILIP E EMPEY

#	Article	IF	CITATIONS
91	Dosing and safety of cyclosporine in patients with severe brain injury. Journal of Neurosurgery, 2008, 109, 699-707.	0.9	99
92	Cyclosporin A Disposition following Acute Traumatic Brain Injury. Journal of Neurotrauma, 2006, 23, 109-116.	1.7	53
93	Internally-Developed Online Adverse Drug Reaction and Medication Error Reporting Systems. Hospital Pharmacy, 2006, 41, 428-436.	0.4	1
94	Levofloxacin Failure in a Patient with Pneumococcal Pneumonia. Annals of Pharmacotherapy, 2001, 35, 687-690.	0.9	84
95	Survey of ASHP-accredited pharmacy residency programs. American Journal of Health-System Pharmacy, 2000, 57, 2080-2086.	0.5	10
96	Pharmacists closing health disparity gaps through pharmacogenomics. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	0.5	O